PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 11, 2024EClinicalMedicine24 citationsOpen Access

Preventing alpelisib-related hyperglycaemia in HR+/HER2−/PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

View Full Paper
ALAntonio Llombart‐CussacJPJosé Manuel Pérez-GarcíaMBManuel Ruíz Borrego

Key Points

Key points are not available for this paper at this time.

Abstract

Hyperglycaemia is an early and frequent adverse event during alpelisib treatment. METALLICA aimed to evaluate prophylactic metformin to prevent or reduce hyperglycaemia occurrence in patients with HR+/HER2-/

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Llombart‐Cussac et al. (2024) studied this question.

synapsesocial.com/papers/68e6f83cb6db6435876721fehttps://doi.org/10.1016/j.eclinm.2024.102520
Ask AI
Helpful
Bookmark
Share
View Full Paper